Search results for "topoi"

showing 10 items of 701 documents

PRR signaling during in vitro macrophage differentiation from progenitors modulates their subsequent response to inflammatory stimuli.

2017

Toll-like receptor (TLR) agonists drive hematopoietic stem and progenitor cells (HSPCs) to differentiate along the myeloid lineage in vitro and also in vivo following infection. In this study, we used an in vitro model of HSPC differentiation to investigate the functional consequences (cytokine production) that exposing HSPCs to various pathogen-associated molecular patterns (PAMPs) and Candida albicans cells have on the subsequently derived macrophages. Mouse HSPCs (Lin- cells) were cultured with GM-CSF to induce macrophage differentiation in the presence or absence of the following pattern recognition receptor (PRR) agonists: Pam3CSK4 (TLR2 ligand), LPS (TLR4 ligand), depleted zymosan (wh…

0301 basic medicinemedicine.medical_treatmentClinical BiochemistryImmunologyProinflammatory cytokineMajor Histocompatibility Complex03 medical and health scienceschemistry.chemical_compoundMicemedicineEscherichia coliImmunology and AllergyAnimalsAntigens LyProgenitor cellCells CulturedChemistryMacrophagesZymosanPattern recognition receptorCell DifferentiationFlow CytometryCell biologyMice Inbred C57BLHaematopoiesisTLR2030104 developmental biologyCytokineReceptors Pattern RecognitionTLR4CytokinesFemaleSignal TransductionEuropean cytokine network
researchProduct

Molecular Pathways Mediating Immunosuppression in Response to Prolonged Intensive Physical Training, Low-Energy Availability, and Intensive Weight Lo…

2019

Exercise and exercise-induced weight loss have a beneficial effect on overall health, including positive effects on molecular pathways associated with immune function, especially in overweight individuals. The main aim of our study was to assess how energy deprivation (i.e., "semi-starvation") leading to substantial fat mass loss affects the immune system and immunosuppression in previously normal weight individuals. Thus, to address this hypothesis, we applied a high-throughput systems biology approach to better characterize potential key pathways associated with immune system modulation during intensive weight loss and subsequent weight regain. We examined 42 healthy female physique athle…

0301 basic medicinemedicine.medical_treatmentPhysiologyliikuntaOverweightSystemic inflammationLeukocyte Countphysical training0302 clinical medicineWeight lossLeukocytesImmunology and AllergyMedicineOXIDATIVE STRESSta315DIETARY RESTRICTIONSport and Fitness SciencesOriginal Research2. Zero hungerimmunosuppressionIdrottsvetenskapbioinformatiikkaImmunosuppressionbioinformaticslow energy availability3. Good healthimmuunivasteIMMUNE FUNCTIONOBESITYChemokine secretionFemalemedicine.symptomfyysinen aktiivisuusAdultlcsh:Immunologic diseases. AllergyImmunologyEXERCISEInflammationYoung Adult03 medical and health sciencesLEPTINImmune systemINFLAMMATIONImmune ToleranceHumansimmunosuppression ; low energy availability ; physical training ; bioinformatics ; weight lossCell Proliferationbusiness.industrylaihdutusCYTOKINESmedicine.diseaseObesityDietenergiansaanti030104 developmental biologyHEMATOPOIETIC STEMImmunoglobulin G3121 General medicine internal medicine and other clinical medicineCELLS3111 Biomedicineweight lossEnergy IntakeTranscriptomelcsh:RC581-607business030215 immunologyFrontiers in Immunology
researchProduct

Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses

2016

Lau et al. show that the FLT3-ITD mutation directly affects dendritic cell development in preleukemic mice, indirectly modulating T cell homeostasis and supporting the expansion of regulatory T cells.

0301 basic medicinemedicine.medical_treatmentT cellT-LymphocytesImmunologyDown-RegulationBiologyCD8-Positive T-LymphocytesArticle03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesGene DuplicationmedicineImmunology and AllergyAnimalsHomeostasisCell LineageProgenitor cellResearch ArticlesCell ProliferationLeukemiaCell growthGene Expression Regulation LeukemicMyeloid leukemiaMembrane Proteinshemic and immune systemsDendritic CellsCell biologyImmunosurveillanceMice Inbred C57BLHaematopoiesis030104 developmental biologyCytokinemedicine.anatomical_structureImmunologyMutationCD8030215 immunologySignal TransductionThe Journal of Experimental Medicine
researchProduct

Organotypic Epigenetic Signature Predicts Bone and Marrow Niche Forming Capacity of Stromal Progenitors in a Novel Mouse Model in Vivo.

2012

Abstract Abstract 2987 Mesenchymal stem/progenitor cells (MSPCs) from numerous tissues are currently tested in clinical trials despite a limited understanding of their in vivo behavior. In this study we used MSPCs from adult and fetal tissues to select the appropriate source for clinical application. We asked whether MSPCs derived from human bone marrow (BM), white adipose tissue (WAT) and umbilical cord (UC), compared to skin fibroblasts, bear an equivalent bone and marrow niche formation potential with of in vivo. Furthermore we evaluated attraction and engraftment of murine as well as human hematopoietic stem/progenitor cells (HSPCs) into newly formed MSPC-derived niches. To elucidate po…

0303 health sciencesPathologymedicine.medical_specialtyStromal cellImmunologyMesenchymal stem cellCD34Cell BiologyHematologyBiologyBiochemistryTransplantation03 medical and health sciencesHaematopoiesis0302 clinical medicinemedicine.anatomical_structuremedicineCancer researchBone marrowProgenitor cellStem cell030304 developmental biology030215 immunologyBlood
researchProduct

Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute …

2014

Abstract Background:Despite recent advances in identifying novel molecular targets in AML patients, intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) still remains a cornerstone of AML therapy. However, outcome of HSCT depends on the availability of a donor and the donor type. Prior studies comparing HSCT from HLA-matched related donors (MRD) with matched unrelated donors (MUD), demonstrated conflicting results with regards to outcome. These conflicting results might be attributed to the genetic heterogeneity of AML. Aims:To analyze outcome with respect to donor type of 952 AML patients who received HSCT in first complete remission (CR) and were tr…

0303 health sciencesmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologySignificant differenceComplete remissionMyeloid leukemiaCell BiologyHematologyHematopoietic stem cell transplantationBiochemistry3. Good healthTransplantation03 medical and health sciences0302 clinical medicineRisk groupsInternal medicineMolecular targetsmedicineCumulative incidencebusiness030304 developmental biology030215 immunologyBlood
researchProduct

Dual targeting of higher-order DNA structures by azacryptands induces DNA junction-mediated DNA damage in cancer cells

2021

Abstract DNA is intrinsically dynamic and folds transiently into alternative higher-order structures such as G-quadruplexes (G4s) and three-way DNA junctions (TWJs). G4s and TWJs can be stabilised by small molecules (ligands) that have high chemotherapeutic potential, either as standalone DNA damaging agents or combined in synthetic lethality strategies. While previous approaches have claimed to use ligands that specifically target either G4s or TWJs, we report here on a new approach in which ligands targeting both TWJs and G4s in vitro demonstrate cellular effects distinct from that of G4 ligands, and attributable to TWJ targeting. The DNA binding modes of these new, dual TWJ-/G4-ligands w…

AcademicSubjects/SCI00010DNA damage[SDV]Life Sciences [q-bio][CHIM.THER] Chemical Sciences/Medicinal ChemistryCellAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerSynthetic lethality[CHIM.THER]Chemical Sciences/Medicinal ChemistryStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compound0302 clinical medicineChemical Biology and Nucleic Acid Chemistry[SDV.CAN] Life Sciences [q-bio]/CancerNeoplasmsGeneticsmedicineHumans[CHIM]Chemical Sciences030304 developmental biology0303 health sciencesbiologyTopoisomeraseDNASmall moleculeIn vitroCell biologyG-Quadruplexesmedicine.anatomical_structurechemistry030220 oncology & carcinogenesisCancer cellMCF-7 Cellsbiology.proteinAzabicyclo CompoundsDNADNA Damage
researchProduct

Acute Nonlymphocytic Leukemia in Adults: Pathophysiology, Status of Current Therapy, and New Approaches

1987

Recent information concerning the cell biology of leukemias has provided new insights into the pathophysiology and pathogenesis of acute leukemia, involving the detection of leukemia viruses, oncogenes and their products, and the discovery of factors supporting clonal leukemic growth. Murine, avian, and cat leukemia viruses are well characterized. To date, only HTLV I appears to be a likely candidate as a human leukemia virus. For both avian and murine viruses, there is a fundamental classification distinction between long-latency viruses (LLV) and acute transforming viruses (ATV). The ATV are replication defective and must be propagated with a helper virus. They have within their genome an…

Acute leukemiaHaematopoiesisLeukemiaAcute myeloblastic leukemiaHelper virusmedicineHairy cell leukemiaBiologymedicine.diseaseVirologyVirusLong terminal repeat
researchProduct

Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia

2013

Abstract Background Cyto- and molecular-genetic abnormalities evaluated at initial diagnosis are the most powerful prognostic and in part also predictive markers in acute myeloid leukemia (AML) with regard to achievement of complete remission (CR) and survival. Nonetheless, after relapse the prognostic impact of clinical characteristics and genetic abnormalities assessed at initial diagnosis with respect to achievement of subsequent CR and survival are less clear. Aims To evaluate the probability of CR achievement and survival in relapsed AML patients in correlation to clinical characteristics and genetic abnormalities assessed at initial diagnosis as well as treatment strategy. Methods The…

Acute promyelocytic leukemiaOncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentImmunologySalvage therapyCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseasePomalidomideBiochemistryChemotherapy regimenSurgeryInternal medicineCEBPACytarabineMedicinebusinessmedicine.drugBlood
researchProduct

Towards More Specificity and Effectivity in the Antileukemia Immune Response

2014

Experimental and clinical studies have shown that alloreactive T-cell responses derived from donor lymphocytes can effectively eliminate leukemia cells after allogeneic hematopoietic stem cell transplantation. However, there are still too many patients in whom this graft-versus-leukemia reactivity is insufficient to prevent leukemia relapse or who suffer from severe alloreactivity to nonmalignant host tissues also mediated by donor-derived T cells. Therefore, various conceptually different approaches have been developed at the level of donor T cells in order to improve the efficacy of leukemia-directed immunity while reducing the incidence of unwanted graft-versus-host disease. As outlined …

Acute promyelocytic leukemiabusiness.industrymedicine.medical_treatmentMyeloid leukemiaHematopoietic stem cell transplantationmedicine.diseaseDonor LymphocytesMinimal residual diseaseTransplantationLeukemiaImmune systemImmunologyMedicinebusiness
researchProduct

Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

2013

Abstract Background Overall survival (OS) in acute myeloid leukemia (AML) treated with intensive chemotherapy has improved over the last 20 year especially in younger adults (18-60 years) but still remains poor in older patients (>60 years) (Döhner et al. Blood 2010). The German-Austrian AMLSG performed controlled prospective treatment trials since 1993 starting with a risk-adapted approach (phase I, 1993-1997), followed by randomized and risk-adapted treatment strategies based on cytogenetic risk groups (phase II, 1997-2002); since 2003 addition of differentiating agents and HiDAC inhibitors to intensive induction therapy was evaluated (phase III, 2003-2007). Of note, until 2007 younger…

Acute promyelocytic leukemiamedicine.medical_specialtyPediatricsmedicine.medical_treatmentImmunologyHematopoietic stem cell transplantationBiochemistry03 medical and health sciences0302 clinical medicineInternal medicinemedicineMyelofibrosisNeoadjuvant therapy030304 developmental biology0303 health sciencesChemotherapybusiness.industryMortality rateCell BiologyHematologymedicine.diseasePomalidomideChemotherapy regimen3. Good healthbusiness030215 immunologymedicine.drugBlood
researchProduct